Thermo Fisher Scientific Inc. has announced a strategic collaboration with NVIDIA to integrate artificial intelligence into scientific instrumentation and laboratory operations, aiming to transform how research is conducted. The partnership will leverage NVIDIA’s AI platform, including technologies like NVIDIA DGX Spark, NeMo, and BioNeMo, to enhance the automation, accuracy, and speed of laboratory workflows. The collaboration focuses on modernizing traditional lab processes that still rely heavily on manual tasks such as experiment design, sample preparation, instrument setup, and data interpretation. By embedding AI into scientific instruments and connecting lab systems to intelligent software, the companies aim to create smarter, more connected laboratories. This integration will allow scientists to work more efficiently, reduce human error, and accelerate discovery across life sciences and other research fields. Gianluca Pettiti, Executive Vice President at Thermo Fisher Scientific, emphasized the transformative potential of AI in research. He stated that combining Thermo Fisher’s deep expertise in laboratory technologies with NVIDIA’s advanced AI infrastructure will help customers achieve faster results, improve data accuracy, and extract greater value from each experiment—ultimately driving breakthroughs with real-world impact. Kimberly Powell, Vice President of Healthcare at NVIDIA, highlighted the vision of “lab-in-the-loop” science, where AI, intelligent agents, and connected instruments work together to scale discovery at an industrial pace. She described the collaboration as foundational to building autonomous labs that can operate with minimal human intervention, creating a powerful feedback loop that accelerates innovation in life sciences. Thermo Fisher’s ecosystem of instruments, software, consumables, and services will be enhanced through this partnership, enabling seamless integration of data, tools, and researchers into a unified digital environment. This approach is designed to significantly boost laboratory productivity and support complex scientific challenges in areas such as drug development, diagnostics, and biotechnology. Thermo Fisher Scientific, a global leader in serving science with over $40 billion in annual revenue, continues to expand its role in advancing scientific discovery. The company’s brands—including Thermo Scientific, Invitrogen, Fisher Scientific, and PPD—serve researchers, healthcare providers, and pharmaceutical developers worldwide. The announcement includes forward-looking statements regarding the expected impact of the collaboration. These statements involve risks and uncertainties, including technological challenges, market adoption, and external factors beyond the company’s control. Thermo Fisher notes that actual results may differ materially and refers investors to its SEC filings for a full discussion of risk factors. The company does not undertake any obligation to update these statements, even if new information becomes available.